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Abstract
Plants synthesize and preserve a variety of metabolites known as natural
products. Many of them are easily extractable and can be used as starting material
or chemical scaffolds for various purposes, especially in drug discovery. Numbers
of reports have listed valuable candidates with privilege scaffolds currently in active
development as drugs. New compounds with anticancer and antiinfective activities
have been discovered recently, some presented these backbones. The present book
chapter aims to highlight these findings from plants which can be considered
valuable for the development of new drugs against malignant cells and infective
diseases. Interest in anti-infective agents is increasing due to the resistance of
microorganisms to existing drugs and newly emerging infectious diseases. This
resistance is also, nowadays, associated to some forms of cancers. In addition, the
value of plants as essential part in the health care pipeline in low- and middle-
income countries is under consideration even though these countries are almost all
surrounded by a rich and untapped biodiversity. People are always relying on
“modern drugs and treatment” which is unfortunately not affordable to all.
Therefore, the present compilation of data on plant-derived compounds can inspire
the formulation of ameliorated traditional medicines (ATM) against the targeted
diseases and the conservation of species.
Keywords: phytoconstituents, anticancer, antimicrobial, biological cutoff points,
sesquiterpenoid lactones, phenolic compounds
1. Introduction
1.1 General statement
As any other organisms on Earth, plants are said to possess multi-functional prop-
erties. They constitute feedstockmaterials to feed people and are reputed for their uses
in medicines [1, 2]. History of plants has been always related to that of Human.
Reports said Human have always insured their primary health care by using plants
[3–5]. Even with the discovery of technology leading to synthetic drugs with some-
times more efficiency, plants still remain ubiquitous and safe for health concerns.
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Research currently overflows in the literature related to the chemistry and
biology of plants. Interests focus on experimental validation of ethnopharma-
cological uses of certain herb and formulation of plant extracts for a sustainable
health care [1–5]. Therefore, plants are ground, exhausted and evaluated for various
biological activity including properties to inhibit the growth of or to kill microor-
ganisms and tumor cell lines. However, both microorganism and cancer cells
become more and more resistant and remain serious threats for life. As an example,
resistance to penicillin used for the treatment of lung infection ranged from 0 to
51% around the World and between 8 and 65% Escherichia coli associated with
urinary tract infections presented resistance to ciprofloxacin, another antibiotic
(https://www.who.int/health-topics/antimicrobial-resistance). WHO took some mea-
sures to diagnose and eradicate the issue but the problem is still actual and present.
More than half of existing antibiotics and anticancers are from synthesis of
which almost a quarter takes its origin in natural substances isolated from plants,
marine organisms and microorganisms [6]. Nevertheless, plant supply extracts
continue to play a relevant role in human beings daily life. Up to date data show that
plant extracts are reputed in food science where they are used as dietary supple-
ments [6–8]. This practice is prevalent in Europe and North America where the
interest in plants and related materials is rising up. Despite the progress made in the
field of the synthesis of active principles for the formulation of medicaments,
people still rely on natural occurring drugs due to their safety and uniqueness.
The list of valuable substances from plants cannot be exhaustive.
In ancient time, the discovery of salicin, an ortho-O-glucopyranosylpheny-
lethanol, from Salix alba led to the development of the reputed anti-inflammatory
agent aspirin [9, 10]. Morphine, a benzylisoquinoline alkaloid isolated from Papaver
somniferum, is a painkiller quite known in medicine and which also exist under its
derivatives, heroin and codeine [9, 10]. Another alkaloid namely quinine isolated
from Cinchona succirubra has been for long employed to cure malaria and fever
related ailments but since 2004, almost all antimalarial drugs in the markets is made
up of artemisinin isolated from the Chinese medicinal plant Artemisia annua.
Artemisinin is commercialized under various acronyms including arteether,
artesunate or artemether [10, 11]. In other hand, the chemotherapy of breast cancer
uses the drug taxol which is the commercial name for paclitaxel, a diterpene isolated
from Taxus brevifolia. Other compounds like ingenol-3-angelate, from Euphorbia
peplus, known under the acronym Ingenol mebutate or the L-histidine-derived
alkaloid pilocarpine found in Pilocarpus jaborandi are also some drugs used against
other form of cancer [12–14].
Days after days, we keep discovering the deeply wealth of our surrounded
nature. Reports abound in the literature especially on valuable natural compounds
in drug development [6–8]. Most of them highlight natural product scaffolds as
building blocks to the development of other compounds through synthesis [6–8].
A list of priority backbones has even been proposed to lead the development of new
drugs [6].
However, interest in health care could also be to find out natural occurring
compounds with considerable effects and low toxicity which can be introduced in
the actual pipelines of treatment of a disease. That is, the sensibility of the found
natural substance is not strong enough to compete commercial drugs but could be
proposed alongside prescribed medicines because of its safety and availability. This
can actually help in low- or middle-income countries to face certain diseases and
build up a sustainable health care system. One can question how useful was the
discovery of artemisinin for indigenous people if they have to wait years for phar-
maceuticals companies to manufacture the drugs before its consumption. The same
interrogation can also be valid to other discovery from plants, e.g. taxol,
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michellamine B or vinblastine. The plant sources of these active substances are
known but still people from villages are waiting for “modern medicines” to take
care of their respective health problems.
1.2 Problematic of microbial infections nowadays: drug resistance and
climate change
According to WHO microbial infections are said to be the second cause of death
globally, with low- and middle-income countries bearing the greatest burden. They
include bacteria or fungi but viruses and protozoa diseases are also listed in this
category (https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resista
nce). Their origin preceded that of human life on earth [15]. In fact, human comes
from successive mutations and evolution of bacteria [15]. Our body is made up of
more than 100 trillion bacteria [16–18]. Some of them are useful in human life
where they played a critical role in metabolism. However, greater percentage of
them has been found to be harmful. By analogy to what is being said by believers,
“you are dust and will return to dust,” one can also argue that “you are bacteria and
will return bacteria.”
A lot of concerted effort has been put forward since the existence of mankind in
trying to understand the biology of infective pathogens and their control. Some
success has been achieved although there still more room for further research on
this area. Through our constant manipulation and uses of these pathogens together
with huge amount of chemicals, including drugs, we end up developing “new
organisms” with different properties compared to their natural counterparts. In
fact, the original pathogens start developing resistance to the drugs that were
previously used for their eradication, making the problem worse [19–22].
The question of resistance of pathogens to commercialized drugs relies on the
living environment of these small organisms. A misconception of bacteria consid-
ered that they exist as individual organisms [23]. However, things are different.
Bacteria accumulated in colonies to live. They generally stick on a surface and
gathered to survive together [23, 24]. Such a constitution known as biofilm is made
up of bacteria somehow wrapped in a certain liquid (extracellular matrix) with
strange properties. The entire constitution acts as a safety membrane for bacteria.
The so-described making-up of this living organism constitutes the first barrier to
bacteria and therefore the first stage of resistance [25, 26]. Biofilm are quite dis-
tributed in hospitals and nursing homes. They are claimed in household and indus-
trial pipes, biomaterials such as contact lenses, medical devices including implants
and urinary catheters, as well as plant and animal tissues. Cases of bacteria resis-
tance have exploded this last decade especially in those zones [23–26]. This includes
bacteria like Acinetobacter, Pseudomonas and various Enterobacteriaceae (Klebsiella,
E. coli, Serratia and Proteus) which cause severe and often deadly infections such as
bloodstream infections and pneumonia. Bacteria are carried over by devices such as
ventilator systems and blood stream catheters. In high-income countries, 7% of all
hospitalized people will contract some form of infection, including one in three
people in intensive care units. In low- and middle-income countries, this figure rises
to at least 10% of hospitalized people, and up to half of people in intensive care
units, said the WHO (https://www.who.int/news-room/fact-sheets/detail/antimic
robial-resistance).
The World is currently facing an unprecedented rising of temperature, leading
to certain change in habits and behavior. Discussion are mainly focused on how it
could have an impact on human life, as it’s getting colder and colder when it is the
cold season or more and more hot when it is the hot season or even hot when it is
supposed to be cold and vice versa. Politics in every country recommend adopting
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new habits to stop the rising up of the earth temperature. In the meantime, it seems
that no one is caring about changes occurring at microorganism scale. It comes out
that changes occurring in microorganisms due to climate change are not so impor-
tant for us. And yet we should beware at least, the occurrences of the new viruses
Ebola and Corona these last years should make us change our mind on how the
World is changing. New microorganisms would be discovered, and the existing
microorganisms could mutate to more harmful organisms. Fortunately, almost the
same changes are also expected in plant kingdom even though the global warming
and deforestation contribute also to plant extinctions. It is also awaited that new
metabolites are being made as a result of new biosynthetical routes. These metabo-
lites could either be directly active against pathogenic microorganisms or inspire
new synthetical routes in laboratories to reach new drugs and medicines.
1.3 Standard antibacterial and anticancer cutoff points
Discussions are ongoing in the literature between scientists to clearly established
standards for a substance to be considered for further steps in drugs development.
Established standards are rare or inaccessible. The Kuete’s group proposed stan-
dards of evaluating antimicrobial or anticancer properties of secondary metabolites
derived from plants. They established that the antimicrobial activity of a crude
extract can be considered significant when it MIC is below 100 μg/mL, moderate
when between 100 and 625 μg/mL and low when more than 625 μg/mL. For pure
compounds, the activity is considered significant when the MIC is below 10 μg/mL,
moderate when between 10 μg/mL < MIC<100 μg/mL or low when greater than
100 μg/mL. One can notice that these standards are not considering the MIC of
standard commercial drug references. We are not saying that the comparison of
obtained MIC with those of the commercial drug is not necessary but the
abovementioned cut-off points precise the ranges for a plant substance to be con-
sidered as valuable in drug discovery. Likewise, an extract is said to possess a good
cytotoxicity if the IC50 values are below 4 μg/mL, modererate when 4 < IC50
< 20 μg/mL/10 < IC50 < 50 μM and low with IC50 above 100 μg/mL (250 μM)
[14, 15]. While for cancer cell lines the activity of the pure compound is consider
strong when IC50 < 10 μM [20, 21].
Another point of constant intensive discussion remains the relative low activity
of most plant extracts and related constituents against microbial and cancer strains.
Their activities are sometimes hundred- or thousand-fold less than the sensitivity of
existing drugs. Some scientists find these activities not significant enough to be
considered for clinical trials as a phytochemical substance should show comparable
sensitivity with the commercial drugs. However, knowing that most cancer treat-
ments are based on chemotherapy which is, as known, as harmful as the disease, can
natural substances replace synthetic compounds? Likewise, one can also question
infectious disease treatments in the same words. In what extent can we clearly
consider a plant based products in drug development with respect to their activity
against strains of bacteria or tumor cell lines? As mentioned above, the objective is
not to compete with existing drugs developed with many expenditures but simply
to select valuable extracts and phytoconstituents which could be used alongside
actual treatments because of their safety and availability status especially for less
developing countries.
1.4 World sustainable development goals related to the field
In September 2015, the UN adopted a list of 17 goals for a better life on the planet
with emphasis on the quality of life for posterity (https://sustainabledevelopment.
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un.org/?menu=1300). Globally it is recognized that ending poverty and other dep-
rivations must go hand-in-hand with strategies that improve health and education,
reduce inequality, and spur economic growth, by tackling climate change and
working to preserve our oceans and forests are essential for our future as human
beings. In the health sector, people should commit themselves to promote healthy
lively hood and well-being for all at all ages. These are objectives stated in the
Sustainable Development Goal number 3 of the list. Targets within this goal include
ending the preventable deaths of newborns and children and ensuring access to
effective medicines to all.
However, we are still living in a place where basic infections (malaria, typhoid,
diarrhea, cholera and others) can cause death; a World where medicines are too
expensive and inaccessible to everyone; a region where people have to walk more
than 10 Km to expect treatment in a hospital or a World with increasing political
and economic crisis. Nowadays, one should also highlight the increasing resistance
of microbes and other pathogens to existing drugs and the occurrence of new strains
of bacteria and virus. The former has been related to the overuse and misuse of
drugs which modify the living pathogens environment making them used to it, thus
developing tolerances to the used drugs.
One of the alternatives to tackle these challenging issues remain natural remedies
and drugs. Many sources are being investigated but plants remain the most
exploited. Substances from plants are quantitative, affordable, reachable and biolog-
ically recognized and easily metabolized by other organisms. They are environmen-
tally friendly and can thus be promoted ever. Numbers of reports are available in the
literature, highlighting the antimicrobial and anticancer properties of phytoextracts
and products. Extracts can then be standardized and proposed to our fellow popula-
tion to alleviate the cost of various and diverse drugs available in the markets.
1.5 Rationale of this survey
The present research literature aims to review recent plant compounds reported
for their anticancer or antimicrobial properties which constitute valuable candi-
dates to drug development. Our survey covers research reported from 2010. We
only listed compounds with MICs or IC50s < 10 μg/mL for a molarity scale ranging
from 106–20 μM. Activities of extracts were not highlighted herein. Both sensitive
and resistant strains were checked out without restriction.
2. Plant-based secondary compounds with antimicrobial properties
Infective diseases are one of the most common illnesses in the World. They are
currently the main concern on earth due to the ongoing Coronavirus (Covid-19)
outbreak. Some pathogens spread out in animals and much of them are not known
so far. But, at one moment or at another, due to our growing familiarization with
wild animals, pathogens can spread within Human kingdom. Research are con-
stantly been done to contain the diseases and come over the pathogens. Most of
them are based on drug discovery, one of the oldest fields of Human concern so far.
Plants constitute the main source of drugs although interests have moved to bioac-
tive microbial constituents in the last decades mainly against microbial infectious.
Owing to the rich biodiversity in our planet, the search for bioactive compounds
from untapped natural resources is among the important ongoing projects.
One of the main constituents of plants with pronounced therapeutic interests
against infective diseases are volatile oil. They are found in almost every organ of a
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plant but are said to be present in high extent in fruits and seeds. The composition
of essential oil consists of monoterpenes and sesquiterpenes paired with aromatic
compounds and lightweight esters, fatty acids, alcohols, ketones and aldehydes.
Some examples include γ-terpinene, carvacrol, p-cymene, thymol, linalool, α-
terpinene, limonene, eucalyptol, geranyl propionate and α- and β-pinene [27].
Owing to their high hydrophobicity, essential oil are said to impair the cell mem-
brane of microbes, increase their membrane permeability and decrease their cyto-
plasmic pH [28]. The so-described abilities explained their significant activity
against bacteria and fungi including resistant strains like Staphylococcus sp. and
Pseudomonas sp. with MIC values approaching 0.01 μg/mL [27]. Volatile oil play
also an essential role in protecting and even preventing biofilm development which
is very important as presented above [29]. However, the same lipophilicity capacity
of essential oil, relevant for their good antiinfective properties, constitutes also their
Family Species (part) Compound name Test microorganisms (MIC
in μg/mL)
Refs.
Guttiferae Garcinia
mangostana
Mangostin A (1) MRSA (6.25 μg/mL), VRE
(3.13 μg/mL)
[30]
Garcinia cowa
(fruits)
B. cereus (0.5 μg/mL), B.
subtilis (0.25 μg/mL),M.
luteus (1.0 μg/mL)
[31]
Garcinia
mangostana
Mangostin Y (2) MSSA (6.25 μg/mL), MRSA
(3.13 μg/mL), VRE (6.25 μg/
mL), VSE (6.25 μg/mL)
[30]
Garcinia cowa
(stem barks)
Cowanol (3) MRSA SK1 (2 μg/mL), S.
aureus (8 μg/mL)
[32]
Cowagarcinone E (4) MRSA SK1 (8 μg/mL)
Garciniacowone (5) MRSA SK1 (2 μg/mL), S.
aureus (2 μg/mL)
Cowanin (6) MRSA SK1 (4 μg/mL)
Garcinia cowa
(fruits)
B. subtilis (4 μg/mL),M.
luteus (4 μg/mL)
[31]
Garcinia cowa
(fruits)
Garcicowanone A (7) B. cereus (0.25 μg/mL), B.
subtilis (2 μg/mL), M. luteus
(4 μg/mL),
9-Hydroxycalabaxanthone
(8)
B. cereus (8 μg/mL), B. subtilis
(2 μg/mL),M. luteus (4 μg/
mL),
B-mangostin (9) B. cereus (0.25 μg/mL), B.
subtilis (4 μg/mL)
Cowagarcinone E (10) B. cereus (4 μg/mL), B. subtilis
(4 μg/mL),M. luteus (8 μg/
mL)
Rubraxanthone (11) B. cereus (2 μg/mL), B. subtilis
(1 μg/mL),M. luteus (2 μg/
mL)
Garcinia
smeathmannii
(stem barks)
1,3,5,8-Tetrahydroxy-2- (3-
methy but-2-enyl)-4- (3,7-
dimethylocta-2,6- dienyl)
xanthone (12)
E. faecalis (8 μg/mL) [33]
Cheffouxanthone (13) E. faecalis (8 μg/mL)
Ananixanthone (14) E. faecalis (2 μg/mL)
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Family Species (part) Compound name Test microorganisms (MIC
in μg/mL)
Refs.
Clusiaceae Allanblackia
gabonensis
(fruits)
Morelloflavone (15) ATCC8739 (8 μg/mL) [34]
Myristicaceae Pycnanthus
angolensis (roots)
Pycnanthulignene A (16) MRSA (9.8 μg/mL) [35]
3,4-Dimethoxy-30,40-
methylenedioxy-7,70-
epoxylignan (17)
M. smegmatis (9.8 μg/mL)
4,5-Dimethoxy-30,40-
methylenedioxy-2,70-
cycloligna-7,70-diene (18)
M. tuberculosis (9.8 μg/mL)
Dioscoreaceae Dioscorea
bulbifera
(Bulbil)
Bafoudiosbulbins C (19) M. smegmatis ATCC700084,
M. tuberculosis ATCC27294
andM. tuberculosisMTCS2
(8 μg/mL)
[36]
Clusiaceae Garcinia nobilis
(stem bark)
4-Prenyl-2-(3,7-dimethyl-
2,6-octadienyl)-
1,3,5,8tetrahydroxyxantho
ne (20)
M. tuberculosis ATCC27294
andM. tuberculosisMTCS2
(8 μg/mL)
[37]
Moraceae Dorstenia manii
(roots)
Dorsmanin C (21) P. aeruginosa PA 01 and E. coli
ATCC 10536 (4 μg/mL)
[38]
Dorsmanin F (22) P. aeruginosa PA 01 and E. coli
ATCC 10536 (4 μg/mL), K.
pneumonia PA01 (8 μg/mL)
Dorsmanin E (23) Candida albicans TCC9002
(8 μg/mL)
Ficus exasperata
(stem bark)
(S)-() Oxypeucedanin
hydrate (24)
B. cereus (9.76 μg/mL) [39]
(R)-(+) Oxypeucedanin
hydrate (25)
Trilepisium
madagascariense
(stem bark)
Dihydrokaempferol (26) E. coli ATCC8739 (8 μg/mL) [40]
Rutaceae Fagara
tessmannii
(roots)
Bergenin (27) E.AG102 and K. pneumoniae
ATCC 11296 (4 μg/mL)
E. coli ATCC 8739, K.
pneumoniae ATCC 11296, K.
pneumoniae KP 55, P. stuartii
PS 299645 and P. aeruginosa
PA01 (8 μg/mL)
[41]
Hypericaceae Harungana
madagascariensis
(bark)
Ferruginin (28) E. coli ATCC 10536, K.
pneumoniae K2 and E. cloacae
BM 67 (4 μg/mL)
E. aerogenes ATCC 13048, E.
aerogenes EA 294, P.
aeruginosa PA01 and K.
pneumoniae KP 55 (8 μg/mL)
K. pneumonia ATCC 11296, E.
cloacae BM 47 and E. coli
ATCC 8739, E. aerogenes
ATCC 13048, K. pneumoniae
KP 55, P. stuartii (8 μg/mL)
[42]
Fabaceae Erythrina
sigmoidea
(leaves)
Neobavaisoflavone (29) E. coli ATCC 8739, E. cloacae
ECC 169, K. pneumoniae KP
55, P. stuartii NAE16 and P.
aeruginosa PA01 (8 μg/mL)
[43]
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Family Species (part) Compound name Test microorganisms (MIC
in μg/mL)
Refs.
P. stuartii ATCC 29916, E.
cloacae BM 47 (4 μg/mL)
Moraceae Milicia excels
(roots and
leaves)
2-(3,5-Dihydroxyphenyl)
benzofuran-5,6-diol (30)
E. coli ATCC 8739, K.
pneumonia ATCC 11296, E.
cloacae BM 47 (4 μg/mL)
E. coli AG 102 and K.
pneumoniae KP 55 (8 μg/mL)
[44–
46]
Candidone (31)
Myristicaceae Myristica
fragrans (seeds)
30,40,7-Trihydroxyflavone
(32)
E. coli ATCC 8739 (8 μg/mL)
P. stuartii ATCC (199645)
(4 μg/mL)
[47, 48]
Hypericaceae Hypericum
roeperianum
(stem Bark)
1,4,6,7-
Tetrahydroxyxanthone (33)
P. aeruginosa PA01 (2 μg/mL) [49]
Fabaceae Entada
abyssinica
(leaves)
Entadanin (34) S. typhimurium (1.56 μg/mL) [50]
Quercitrin (35) S. typhimurium (3.12 μg/mL)
Meliaceae Pseudocedrela
kotschyi (stem
bark)
3,4-Secotirucalla- 4
(28),7,24-trien-3,21- dioic
acid (36)
S. aureus (4 μg/mL) [51]
3,4-Secotirucalla- 4
(28),7,24-trien-3,21- dioic
acid (36) and 3- methyl ester
3,4- secotirucalla-4(28),7,24-
trien-3,21-dioic (37) (1:1)
S. aureus (8 μg/mL)
Rubiaceae Crossopteryx
febrifuga (stem
bark)
l8-epi-3β-D-
Glucopyranosylurs- l2,20
(30)diene-27,28- dioic acid
(38)
K. pneumoniae ATCC11296
(8 μg/mL)
[52]
Lamiaceae Leucosceptrum
canum (aerial
part)
4-En-3-keto-stigmasterol
(39)
M. luteus (9.5 μg/mL) [53]
Stigmast-5-en-3-acetate (40) M. luteus (4.2 μg/mL)
40,5,7-Trihydroxy-6
methoxyflavone (41)
M. luteus (6.5 μg/mL)
Leucoperoxyterpene (42) M. luteus (5.4 μg/mL) and S.
minor (5.4 μg/mL)
Caryophyllaceae Silene rubella
(aerial part)
Oleanolic acid (43) VRE (6.36 μg/mL) [54]
Fabaceae Entada
abyssinica
(leaves)
Ursolic acid (44) B. cereus (6.25 μg/mL) [55]
Methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), methicillin-sensitive
Staphylococcus aureus (MSSA), vancomycin-sensitive Enterococcus (VSE), Staphylococcus aureus (S. aureus), Bacillus
subtilis (B. subtilis), Bacillus cereus (B. cereus), Micrococcus luteus (M. luteus), Mycobacteria smegmatis (M. smegmatis),
Mycobacteria tuberculosis (M. tuberculosis), Pseudomonas aeruginosa (P. aeruginosa), Escherichia coli (E. coli), Klebsiella
pneumonia (K. pneumonia), Candida albicans (C. albicans), Bacillus cereus (B. cereus), Escherichia coli (E. coli),
Klebsiella pneumoniae (K. pneumoniae), Providencia stuartii (P. stuartii), Pseudomonas aeruginosa (P. aeruginosa),
Enterobacter cloacae (E. cloacae), Enterobacter aerogenes (E. aerogenes), Salmonella typhimurium (S. typhimurium),
Staphylococcus aureus (S. aureus), Micrococcus luteus (M. luteus), Streptococcus minor (S. minor), Vancomycin resistant
Enterococcus (VRE).
Table 1.
Examples of plant-based natural products with significant antiinfective properties.
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Figure 1.
Bioactive compounds against infective bacteria and fungi.
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main bottlenecks in drug development because essential oil present a low bioavail-
ability. But when isolated, some of their constituents are water soluble e.g. 1.25 mg/
mL at 25°C for carvacrol (https://pubchem.ncbi.nlm.nih.gov/compound/carvac
rol#section=Solubility) or 1.59 mg/mL at 25°C (https://pubchem.ncbi.nlm.nih.gov/c
ompound/6549) for linalool and are being studied and used as excipient in drug
formulation. Essential oil are however reputed in therapies which promoted local
application, inhalation or bath modes of treatment like aromatherapy [27, 56]. They
are associated to numerous of ailments including depression, indigestion, headache,
insomnia, muscular pain, respiratory problems, skin ailments, swollen joints or
urine complications [56]. Unlike essential oil, secondary metabolites mainly found
in the solid part of a plant extract can present significant activities with considerable
bioavailability and hence, constitute the main research object in natural product
domain.
Since 2010 at least 44 metabolites have been reported with MIC values below
10 μg/mL. Phenolic compounds (1–18, 20–26, 28–35, 41) were the group of com-
pounds mostly active among the metabolites found. Besides, benzophenanthridine
(27), steroids (36–37, 40), pentacyclic triterpenoids (38–39, 43–44) and
diterpenoids (19, 42) have been found active against various infective strains
(Table 1 and Figure 1). Some of the strains studied are among the microbes listed
by WHO as highly harmful and needed new drugs.
3. Plant-based compounds with anticancer features
The chemistry and biology of plants to fight against malignant cells are wide and
diverse. Various classes of metabolites have been reported to possess valuable
anticancer properties. As a recall, taxol, one of the mostly used anticancer drug in
chemotherapy, is a complex diterpene-based metabolite; vinblastine, used in the
therapy of various cancer as well, is made up of terpenic indol-type alkaloids and
artemisinin or parthenolide actually in active clinical trials for cancer drugs possess
a sesquiterpenoid lactone backbone. Since 2010, more than 72 compounds have
Family Species (part) Compound name Cancer cell lines (IC50) Refs.
Asparagaceae Bellevalia eigii
(bulbs)
5,7,30-triihydroxy-40- methoxy
Homoisoflavanone (45)
MDA-MB-435 (1.0 μM) [57]
5,30-dihydroxy-40,7,8-
trimethoxy
Homoisoflavanone (46)
MDA-MB-435 (1.1 μM)
7-O-methyl-30-
hydroxypunctatin (47)
MDA-MB-435 (4–6 μM)
Bellevalia
flexuosa (bulbs)
30-hydroxy-3,9-
dihydroeucomin (48)
MDA-MB-435 (1–6 μM); MDA-
MB- 231 (9–5 μM)
[58]
Asparagaceae Urginea depressa
(whole plant)
Urgineanin A (49) H522-T1 (0–071 μM); A2780
(0.32 μM); A2058 (0.068 μM)
[59]
Urgineanin B (50) H522-T1 (6.78 μM); A2780
(3.4 μM)
Urgineanin C (51) H522-T1 (0.74 μM); A2780
(1.35 μM), A2058 (0.69 μM)
Urgineanin D (52) H522-T1 (0.43 μM); A2780
(0.35 μM), A2058 (0.38 μM)
Urgineanin E (53) A2780 (1.44 μM)
Urgineanin F (54) A2780 (2.3 μM)
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Family Species (part) Compound name Cancer cell lines (IC50) Refs.
Convallariaceae Ophiopogon
japonicus
(tubers)
Homoisopogon A (55) KB (0.51 μM); LU-1 (0.66 μM);
SK- Mel-2 (0.66 μM)
[60]
Ophiopogon
japonicus
(roots)
5,7,40-Trihydroxy-30-
methoxy-6,8-
dimethylhomoisoflavanone
(56)
A549 (6.40 μM) [61]
Methylophiopogonanone B
(57)
A549 (0.84 μM)
Methylophiopogonanone A
(58)
A549 (1.66 μM)
Liliaceae Scilla persica
(bulbs)
Scillapersicene (59) AGS (8.4 μM) [62]
Amaryllidaceae Crinum
zeylanicum
(whole plant)
Ungeremine (60) CCRF-CEM (4.89 μM);MDA-
MB - 231-pcDNA (5.47 μM);
MDA-MB- 231-BCRP (3.67 μM);
HCT116 (p53+/+) (6.45 μM)
HCT116 (p53/) (7.06 μM);
U87MG (5.38 μM)
[63]
Euphorbiaceae Macaranga
balansae
(fruits)
6,8-Diprenyl-4-methyl-
naringenin (61)
Pan C1 (7.89 μM) [64]
(2S)-6-Farnesylnaringenin
(62)
P388 (3.27 μg/mL)
6-Farnesyl-30,40,5,7-
tetrahydroxy flavanone (63)
P388 (2.61 μg/mL)
Macaranga
triloba
(inflorescences)
HeLa (1.3 μg/mL), HL-60
(3.3 μg/mL)
[65]
Euphorbiaceae Macaranga
tanarius (fruits)
Vedelianin (64) KB (0.050 μM), MCF-7
(0.050 μM)
[66]
Schweinfurthin E (65) KB (0.050 μM), MCF-7
(0.030 μM)
Schweinfurthin F (66) KB (0.10 μM), MCF-7
(0.12 μM)
Schweinfurthin H (67) KB (0.26 μM)
Thelypteridaceae Cyclosorus
parasiticus
(leaves)
Parasiticin C (68) SW1990 (2.33 μM), MDA-MB-
231 (4.88 μM),
MCF-7 (4.16 μM), HepG2
(1.6 μM), A.549 (5.50 μM),
ALLSIL (6.06 μM)
[67]
20,40-Dihydroxy-60-methoxy-
30,50-Dimethylchalcone (69)
SW1990 (6.64 μM),
MDA-MB-231 (9.67 μM),
MCF-7 (8.49 μM), HepG2
(2.82 μM), A549 (7.89 μM),
ALLSIL (9.50 μM)
Moraceae Artocarpus
obtusus (stem
bark)
Pyranocycloartobiloxanthone
A (70)
HL60 (0.5 μg/mL), K562
(2.0 μg/mL)
[68]
Guttiferae Calophyllum
soulattri (stem
bark)
Soulattrin (71) Raji (1.01 μM/mL), LS174T
(1.25 μM/mL), IMR-32 (0.27 μg/
mL), SK-MEL-28 (0.57 μM/
mL).
[69]
Guttiferae Garcinia
xanthochymus
(stem bark)
1,3,5,6-T etrahydroxy-4,7,8-tri
(3-methylbut-2-enyl)
xanthone (72)
PC-3 (6.8 μM) [70]
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Family Species (part) Compound name Cancer cell lines (IC50) Refs.
Papaveraceae Macleaya
microcarpa
(roots)
Maclekarpine A (73) BGC-823 (0.7 μM) [71]
Maclekarpine C (74) HCT-8 (1.9 μM), Bel-7402
(2.1 μM), A2780 (1.6 μM), A549
(3.4 μM)
Maclekarpine D (75) HCT-8 (1.9 μM), BGC-823
(0.2 μM), A2780 (2.0 μM)
Maclekarpine E (76) BGC-823 (0.1 μM)
6-
Methoxydihydrochelerythrine
(77)
HCT-8 (1.1 μM), Bel-7402
(0.9 μM) BGC-823 (0.8 μM),
A2780 (1.8 μM)
Dihydrosanguinarine (78) HCT-8 (1.3 μM), Bel-7402
(2.3 μM) BGC-823 (0.1 μM),
A2780 (2.1 μM)
Dihydrochelerythrine (79) HCT-8 (1.4 μM), BGC-823
(0.4 μM), A2780 (3.5 μM)
6-Butoxydihydrochelerythrine
(80)
HCT-8 (1.7 μM), Bel-7402
(1.3 μM) BGC-823 (0.7 μM)
A2780 (1.8 μM),
Papaveraceae Bis[6-(5,6-
dihydrochelerythrinyl)] ether
(81)
HCT-8 (1.6 μM), Bel-7402
(2.1 μM) BGC-823 (0.1 μM),
A2780 (1.6 μM),
6-
Methoxydihydrosanguinarine
(82)
HCT-8 (0.5 μM), Bel-7402
(0.5 μM) BGC-823 (0.6 μM),
A2780 (0.5 μM), A549 (0.6 μM)
Amaryllidaceae Zephyranthes
candida (whole
plant)
N-methylhemeanthidine
Chloride (83)
HL-60 (0.91 μM), K562
(1.0 μM), A549 (1.1 μM),
HepG2 (1.5 μM), HT-29
(1.2 μM)
[72]
Hemeanthamin (84) HL-60 (1.4 μM), K562 (2.5 μM),
A549 (2.5 μM), HepG2
(4.8 μM), HT-29 (2.1 μM)
Lycorine (85) HL-60 (1.6 μM), K562 (2.3 μM),
A549 (1.9 μM), HepG2
(3.7 μM), HT-29 (3.2 μM)
N-phenethylcrinasiadine (86) HL-60 (1.6 μM), K562 (2.3 μM),
A549 (1.9 μM), HepG2
(3.7 μM), HT-29 (3.2 μM)
Asparagaceae Bellevalia
flexuosa (bulbs)
Urginin B (87) A2780 (0.011 μM), A2058
(0.060 μM), H522-T1
(0.044 μM)
[59]
Urginin C (88) A2780 (0.041 μM), A2058
(0.076 μM), H522-T1
(0.051 μM)
14β-Bydroxy-19β-oxobufa-
4,20, 22-trienolide-3β-O-β-D-
gluco pyranoside (89)
A2780 (0.024 μM), A2058
(0.048 μM), H522-T1
(0.034 μM)
14β-Hydroxybufa-4,20,22-
trien olide-3β-O-{α-L-
rhamnopyranosyl-[(1! 4)-β-
D-glucopyranosyl]-(1! 3)-
α-L-rhamnopyranoside} (90)
A2780 (0.111 μM), A2058
(0.18 μM), H522-T1 (0.11 μM)
Asteraceae Leptocarpha
rivularis
Leptocarpin (91) DU-145 (2.0 μM), PC-3
(4.5 μM), HT-29 (3.8 μM),
MCF7 (3.1 μM), MDA-MB-231
[73]
12
Bioactive Compounds
Family Species (part) Compound name Cancer cell lines (IC50) Refs.
(6.4 μM), CCD 841 CoN
(5.2 μM)
Smallanthus
sonchifolius
(leaves)
Enhydrin (92) CCRF-CEM (3.6 μM) [74]
Uvedalin (93) CCRF-CEM (9.2 μM)
Polymatin B (94) CCRF-CEM (0.8 μM), CEM-
ADR5000 (1.3 μM), MIA-PaCa-
2 (3.7 μM)
Sonchifolin (95) CCRF-CEM (3.1 μM), CEM-
ADR5000 (3.1 μM), MIA-PaCa-
2 (7.4 μM)
8β-Angeloyloxy-9α-hydroxy-
14-oxo-acanthospermolide
(96)
CCRF-CEM (2.2 μM), CEM-
ADR5000 (6.7 μM), MIA-PaCa-
2 (8.9 μM)
Fluctuanin (97) CCRF-CEM (0.6 μM), CEM-
ADR5000 (1.4 μM), MIA PaCa-
2 (4.4 μM)
Ambrosia
cumanensis
(aerial parts)
2,3-Dehydropsilostachyn C
(98)
Jurkat (6.0 μM), U937 (8.0 μM) [75]
Sonchus
palustris (roots)
15-p-
Hydroxyphenylacetyllactucin
(99)
CEM (5.1 μM), BJ (9.8 μM) [76]
15-p-
Methoxyphenylacetyllactucin
(100)
CEM (3.9 μM), BJ (8.4 μM)
Compositae Carpesium
abrotanoides
(whole plant)
Caroguaianolide A (101) MDA-MB-231 (7.96 μM) [77]
Caroguaianolide B (102) MDA-MB-231 (4.25 μM), HGC-
2 (6.47 μM)
Carpesium
abrotanoides
(whole plant)
Caroguaianolide C (103) MDA-MB-231 (2.67 μM), HGC-
2 (4.83 μM)
Akihalin (104) MDA-MB-231 (4.83 μM), HGC-
2 (7.35 μM)
4β-Hydroxy,l0β-
hydroperoxyl,5αh,7αh,8βh-
guaia-1,11(13)- dien-8α,12-
olide (105)
MDA-MB-231 (5.79 μM)
4α-Hydroxy-1βh-guaia-9,11
(13)-dien-12,8α-olide (106)
MDA-MB-231 (4.07 μM), HGC-
2 (8.95 μM)
(3ar,4as,5S,7as,8S,9ar)-5-
Hydroxy-4a,8-dimethyl-
3-methylen-decahy
droazuleno[6,5-b]furan- 2
(3H)-on (107)
MDA-MB-231 (5.32 μM)
Carpesium
faberi (whole
plant)
Guaianodilactones A (108) CCRF-CEM (9.13 μM) [78]
Guaianodilactones C (109) CCRF-CEM (4.74 μM)
Guaianodilactones B (110) CCRF-CEM (2.03 μM)
Asteraceae Inula japonica
(aerial part)
Neojaponicone B (111) Jurkat (5.9 μM), 6 T-CEM
(4.4 μM)
[79]
Inulanolide E (112) Jurkat (5.5 μM), 6 T-CEM
(4.6 μM)
Inulanolide A (113) Jurkat (5.8 μM), 6 T-CEM
(4.3 μM)
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been reported with considerable antiproliferative activity against different cancer
cell lines with IC50 ranging from 0.001–10 μM.
These compounds are distributed in homoisoflavonoids (45–60), isoprenyl-
flavonoids (61–63, 68–70), stilbenoids (64–67), xanthones (71–72), benzophenan-
thridines (73–82), Amaryllidaceae-type alkaloids (83–86), cardenolides (87–90)
and sesquiterpenoid lactones (91–117). Their respective sensibility toward tumor
cell lines are depicted in Table 2 and their respective structures in Figure 2. As
expected, sesquiterpenoid lactones were the most exploited metabolites. They are
reputed for their ability to induce apoptosis in cancer cell lines with good selectivity.
Homoisoflavonoids were the second most important group of compounds found to
exhibit high cytotoxicity herein. The interest in this class of metabolites for anti-
cancer solution is most likely related to their potency as inhibitor of angiogenesis
both in vitro and in vivo, without showing any toxicity [80]. On the other hand,
benzophenanthridines are reputed for their bioavailability because they contained
more often ionic bond besides their bioactivity. Their mode of action in cancer
therapy includes either the inhibition of mitosis via a reaction of the imine bond
with the sulfhydryl nucleophile in protein and enzyme or the enzymatic activities of
DNA Topoisomerase I and Topoisomerase II by implantation into DNA molecules
to retard the fast proliferation of tumor cells [81].
4. Natural products in active development for drug discovery
Knowing the categories of compounds which has been screened and choose for
clinical trials is quite important. It can help redefine our objectives and outlines in
research. However, such information is not accessible easily. Almost all pharma-
ceutical makers keep this information for private uses. Nevertheless, available
reports before 2010 on valuable compounds in development for cancer therapy for
instance can continue to be used and analyze. There are privilege structures with
Family Species (part) Compound name Cancer cell lines (IC50) Refs.
Japonicone Q (114) Jurkat (3.3 μM), 6 T-CEM
(2.7 μM)
Japonicone N (115) Jurkat (2.5 μM), 6 T-CEM
(2.4 μM)
Japonicone S (116) Jurkat (4.5 μM), 6 T-CEM
(3.3 μM)
Japonicone A (117) Jurkat (3.1 μM) 6 T-CEM
(2.2 μM)
Melanoma (MDA-MB-435, A2058 and SK-Mel-2); human non-small-cell lung (H522-T1), ovarian cancer (A2780),
human epidermoid carcinoma (KB), human lung adenocarcinoma (LU-1), breast (MDA-MB-231), gastric (AGS), human
myeloid leukemia (K562), human gastric (SGC-7901), human-lung-tumor (A549). Murine leukemia (P-388), human
pancreatic (Pan C1 and SW1990), human cervical carcinoma (Hela), mouse leukemia (P388), human leukemia (HL-60
and ALL-SIL), mouth epidermal carcinoma cells (KB), breast cancer (MCF-7 and MDA-MB-231) lung cancer (A549),
hepatocellular carcinoma (HepG2), human promyelocytic leukemia (HL60), human chronic myeloid leukemia (K562), B-
lymphocyte (Raji), colon carcinoma (LS174T), human neuroblastoma (IMR-32), skin carcinoma (SK-MEL-28), colon
(HCT-8), liver (Bel-7402), stomach (BGC-823), ovarian (A2780), lung (A549). Myeloid leukemia (HL-60 and K562),
lung (A549), hepatocellular carcinoma (HepG2), colon (HT-29), ovarien (A2780), melanoma (A2058), non-small-cell
lung cancer (H522-T1), lymphoblastic leukemia cell line (CCRF-CEM), resistant T-cell leukemia cell line (CEM-
ADR5000), the pancreatic, carcinoma cell line (MIA PaCa-2)–, and on peripheral blood mononuclear cells (PBMC) from
healthy human subjects, HeLa (cervical carcinoma), Jurkat (T-cell leukemia), and U937 (monocytic leukemia) cell lines,
human acute lymphoblastic leukemia (CEM), and normal human skin fibroblasts (BJ), human breast (MDA-MB-231),
human gastric (HGC-27), human leukemia (CCRF-CEM).
Table 2.
Examples of significant secondary metabolites with antiproliferative properties.
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Figure 2.
Bioactive compounds against cancer cell lines.
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unique structurally subunits which confer to drugs distinctive therapeutic affinities
to a biological system. These core molecules include β-lactam unit like in penicillin;
cyclopentanoperhydrophenanthrene fragment like in testosterone; pyrone, couma-
rins, isoflavone, or chalcone moieties and alkaloids like quinoline, isoquinoline or
indole units.
As an example, since the large-scale screening for anticancer agents launched in
the USA in 1960, more than 3000 sesquiterpene lactones have been reported. Most
of them are with cytotoxic properties. Sesquiterpene lactones are well-known for
their ability to bind sulfhydryl-containing peptides, mainly in proteins, presented as
important route in well- programed death of a cell [82–85]. This property and other
have raised up interests in this class of compounds. Many members of this class are
currently in clinical trials for drug development including parthenolide, artemisinin
or thapsigargin among others.
Another most important class of phytocompounds in cancer therapy is phenolic
compounds. Members of these classes of metabolites are reputed in caspase activa-
tion causing apoptosis in tumor cell lines. Research found that furanocoumarins for
instance in grapefruit showed significant effects towards breast cancer, the second
World leading cause of cancer-related death among Women [86]. In the same line,
coumarine-type of compounds known as calanolides, isolated from Calophyllum
species have been found to be active against lymphoblastic cells infected with HIV-1
[87]. They are currently in clinical trials Phase II to drug development. Likewise, all
other phenolic compounds listed above can also undergo similar interactions with
cancer cells. Anthraquinones, and quinones, in general form the basic core of many
anticancer drugs known as anthracyclines. Resveratrol, a stilbene-like metabolite, is
being continuously checked to explain issues encountered during laboratory trials
against cancer in animal model. However, association of resveratrol with
established anticancer drugs like clofarabine has been proved against mesothelioma
cell lines [88].
5. Conclusion
The World is facing an unprecedented drastic climate change that impacts
negatively not only on human beings but also plants. New metabolism routes have
surely emerged leading to compounds with unprecedented structures for some and
with relevant bioactivities for others. However, nothing is being done to take
advantages of this wealth for our health care always relying on “modern drugs.”We
should start exploring ways to use natural products with anticancer effects along
with standard chemotherapy treatments to increase potency while reducing side
effects of actual drugs. This strategy is currently being used in the USA. We
highlighted relevant bio-sensibility of some compounds and they should now be
investigated as main constituents to a standardization process of their respective
plant extracts. The present survey can also help researchers in developing countries
working on plants, to re-focus their research works.
Acknowledgements
The authors would like to acknowledge the Yaounde-Bielefeld Graduate School
of Natural Products with Antiparasite and Antibacterial Activities (YaBiNaPA,
www.yabinapa.de) for the research stay granted at the University of Bielefeld in
Germany under the project No. 57316173.
17
Plant-Derived Compounds against Microbial Infections and Cancers
DOI: http://dx.doi.org/10.5772/intechopen.92596
Conflict of interest
The authors declare no conflict.
Author details
Gabin Thierry M. Bitchagno1*, Vaderament-A. Nchiozem-Ngnitedem1,2,
Nadine Tseme Wandji3, Guy Cedric T. Noulala3, Serge Alain T. Fobofou4
and Bruno Ndjakou Lenta3
1 Department of Chemistry, University of Dschang, Dschang, Cameroon
2 Department of Chemistry, University of Nairobi, Nairobi, Kenya
3 Department of Chemistry, Higher Teacher’s Training College, University of
Yaounde I, Yaounde, Cameroon
4 Department of Biological Chemistry and Molecular Pharmacology, Harvard
Medical School, USA
*Address all correspondence to: gabin1256@gmail.com
©2020TheAuthor(s). Licensee IntechOpen. This chapter is distributed under the terms
of theCreativeCommonsAttribution License (http://creativecommons.org/licenses/
by/3.0),which permits unrestricted use, distribution, and reproduction in anymedium,
provided the original work is properly cited.
18
Bioactive Compounds
References
[1] Bitchagno GTM, Schüffler A,
Simo IK, Krumb M, Tane P, Opatz T.
Neo-clerodane diterpenoids from
Conyza pyrrhopappa Sch.Bip. ex A.
Natural Product Research. 2019. DOI:
10.1080/14786419.2019.1690490
[2] Bitchagno MGT, Tankeo BS,
Tsopmo A, Mpetga SDJ, Tchinda TA,
Fobofou TSA, et al. Lemairones A and B:
Two new antibacterial tetraflavonoids
from the leaves of Zanthoxylum lemairei
(Rutaceae). Phytochemistry Letters.
2015;14:1-7. DOI: 10.1016/j.
phytol.2015.08.012
[3]Nganou BK, Mbaveng AT,
Fobofou SAT, Fankam AG,
Bitchagno GTM, Mpetga JDS, et al.
Furoquinolines and dihydrooxazole
alkaloids with cytotoxic activity from
the stem bark of Araliopsis soyauxii.
Fitoterapia. 2019;133:193-199. DOI:
10.1016/j.fitote.2019.01.003
[4]Mbaveng AT, Bitchagno GTM,
Kuete V, Tane P, Efferth T. Cytotoxicity
of ungeremine towards multi-factorial
drug resistant cancer cells and induction
of apoptosis, ferroptosis, necroptosis
and autophagy. Phytomedecine. 2019;
60:152832. DOI: 10.1016/j.phymed
[5] Sonfack G, Tchinda CF, Simo IK,
Bitchagno GTM, Nganou BK, Çelik I,
et al. Saponin with antibacterial activity
from the roots of Albizia adianthifolia.
Natural Product Research. 2019. DOI:
10.1080/14786419.2019.1672689
[6] Barreiro EJ. Privileged scaffolds in
medicinal chemistry: An introduction.
In: Bräse S, editor. Privileged Scaffolds
in Medicinal Chemistry: Design,
Synthesis, Evaluation. RSC Drug
Discovery Series No. 50: Cambridge;
2015. p. 476. DOI: 10.1039/
9781782622246-00001
[7] Butler MS, Robertson AAB,
Cooper MA. Natural product and
natural product derived drugs in clinical
trials. Natural Product Reports. 2014;31:
1612-1661. DOI: 10.1039/C4NP00064A
[8] Butler MS. Natural products to drugs:
Natural product derived compounds in
clinical trials. Natural Product Reports.
2005;22:162-195. DOI: 10.1039/
B514294F
[9]Dias DA, Urban S, Roessner U. A
historical overview of natural products
in drug discovery. Metabolites. 2012;2:
303-336. DOI: 10.3390/metabo2020303
[10]Der Marderosian A, Beutler JA,
editors. The Review of Natural
Products. 2nd ed. Seattle, WA, USA:
Facts and Comparisons; 2002. p. 794
[11]Newman DJ, Cragg GM. Natural
products as sources of new drugs over
the last 25 years. Journal of Natural
Products. 2007;70:461-477. DOI:
10.1021/np068054v
[12] Kedei N, Lundberg DJ, Toth A,
Welburn P, Garfield SH, Blumberg PM.
Characterization of the interaction of
ingenol 3-angelate with protein kinase
C. Cancer Research. 2004;64:3243-3255.
DOI: 10.1158/0008-5472.CAN-03-3403
[13]Ogbourne SM, Suhrbier A, Jones B.
Antitumour activity of ingenol 3-
angelate: Plasma membrane and
mitochondrial disruption and necrotic
cell death. Cancer Research. 2004;64:
2833-2839. DOI: 10.1158/0008-5472.
CAN-03-2837
[14] Aniszewski T. Alkaloids—Secrets of
life. In: Aniszewski T, editor. Alkaloid
Chemistry, Biological Significance,
Applications and Ecological Role.
Amsterdam: The Netherlands: Elsevier
Science; 2007. p. 334
[15]Hartman H, Matsuno K. The Origin
and Evolution of the Cell. Singapore:
World Scientific Publishing Co Pte Ltd;
19
Plant-Derived Compounds against Microbial Infections and Cancers
DOI: http://dx.doi.org/10.5772/intechopen.92596
1993. p. 446. DOI: 10.1142/
9789814536219
[16]American Academy of Microbiology
FAQ: Human Microbiome. Archived 31
December 2016 at the Wayback
Machine
[17] Rosner JL. Ten times more microbial
cells than body cells in humans?
Microbe. 2014;9:47. DOI: 10.1128/
microbe.9.47.2
[18] Abbott A. Scientists bust myth that
our bodies have more bacteria than
human cells. Nature. 2016. DOI:
10.1038/nature.2016.19136
[19] Abreu AC, McBain AJ, Simões M.
Plants as sources of new antimicrobials
and resistance-modifying agents.
Natural Product Reports. 2012;29:
1007-1021. DOI: 10.1039/c2np20035
[20] Kuete V. Potential of Cameroonian
plants and derived products against
microbial infections: A review. Planta
Medica. 2010;76:1479-1491. DOI:
10.1055/s-0030-1250027
[21] Kuete V, Efferth T. African flora has
the potential to fight multidrug
resistance of cancer. BioMed Research
International. 2015;2015:914813. DOI:
10.1155/2015/914813
[22] Cowan MM. Plant products as
antimicrobial agents. Clinical
Microbiology Reviews. 1999;12:564-582.
DOI: 10.1128/CMR.12.4.564
[23]Watnick P, Kolter R. Biofilm, city of
microbes. Journal of Bacteriology. 2000;
182:2675-2679. DOI: 10.1128/
jb.182.10.2675-2679.2000
[24]O’Toole GA, Kolter R. Initiation of
biofilm formation in Pseudomonas
fluorescens WCS365 proceeds via
multiple, convergent signalling
pathways: A genetic analysis. Molecular
Microbiology. 1998;28:449-461. DOI:
10.1046/j.1365-2958.1998.00797.x
[25] Briandet R, Herry J, Bellon-Fontaine
M. Determination of the van der Waals,
electron donor and electron acceptor
surface tension components of static
Gram-positive microbial biofilms.
Colloids and Surfaces. B, Biointerfaces.
2001;21:299-310. DOI: 10.1016/
S0927-7765(00)00213-7
[26] Takahashi H, Suda T, Tanaka Y,
Kimura B. Cellular hydrophobicity of
listeria monocytogenes involves initial
attachment and biofilm formation on
the surface of polyvinyl chloride. Letters
in Applied Microbiology. 2010;50:
618-625. DOI: 10.1111/j.1472-765X.2010.
02842.x
[27]Man A, Santacroce L, Jacob R,
Mare A, Man L. Antimicrobial activity
of six essential oils against a group of
human pathogens: A comparative study.
Pathogen. 2019;8:15. DOI: 10.3390/
pathogens8010015
[28] Lambert RJW, Skandamis PN,
Coote PJ, Nychas G-JE. A study of the
minimum inhibitory concentration and
mode of action of oregano essential oil,
thymol and carvacrol. Journal of
Applied Microbiology. 2001;91:453-462.
DOI: 10.1046/j.1365-2672.2001.01428.x
[29] Saad IK, Hassan L, Ghizlane Z,
Hind M, Adnane R. Carvacrol and
thymol components inhibiting
Pseudomonas aeruginosa adherence and
biofilm formation. African Journal of
Microbiology Research. 2011;5:
3229-3232. DOI: 10.5897/AJMR11.275
[30] Sakagami Y, Thevanesam V,
Programme NP, Lanka S, Lanka S,
Sakagami Y. Antibacterial activity of
xanthones from Garcinia mangostana
(L.) and their structure – Activity
relationship studies. Natural Product
Research. 2013;27:938-941. DOI:
10.1080/14786419.2012.678348
[31]Auranwiwat C, Trisuwan K, Saiai A,
Pyne SG, Ritthiwigrom T. Antibacterial
20
Bioactive Compounds
tetraoxygenated xanthones from the
immature fruits of Garcinia cowa.
Fitoterapia. 2014;98:179-183. DOI:
10.1016/j.fitote.2014.08.003
[32] Siridechakorn I, Phakhodee W,
Ritthiwigrom T, Promgool T.
Antibacterial dihydrobenzopyran and
xanthone derivatives from Garcinia
cowa stem barks. Fitoterapia. 2012;83:
1430-1434. DOI: 10.1016/j.
fitote.2012.08.006
[33] Fouotsa H, Lannang AM,
Dzoyem JP, Tatsimo SJN, Neumann B,
Eloff JN, et al. Antibacterial and
antioxidant Xanthones and
Benzophenone from Garcinia
smeathmannii. Planta Medica. 2015;81:
594-599. DOI: 10.1055/s-0035-1545841
[34]Nganou BK, Konga IS, Fankam AG,
Bitchagno GTM, Sonfack G, Nayim P,
et al. Guttiferone BL with antibacterial
activity from the fruits of Allanblackia
gabonensis. Natural Product Research.
2018;6419:1-9. DOI: 10.1080/
14786419.2018.1465424
[35]Nono ECN, Mkounga P, Kuete V,
Marat K, Hultin PG, Nkengfack AE.
Pycnanthulignenes A-D, antimicrobial
cyclolignene derivatives from the roots
of Pycnanthus angolensis. Journal of
Natural Products. 2010;73:213-216. DOI:
10.1021/np9007393
[36] Kuete V, Nono ECN, Mkounga P,
Marat K, Hultin PG, Nkengfack AE.
Antimicrobial activities of the CH2Cl2–
CH3OH (1:1) extracts and compounds
from the roots and fruits of Pycnanthus
angolensis (Myristicaceae). Natural
Product Research. 2010;25:432-443.
DOI: 10.1080/14786419.2010.522577
[37] Kuete V, Teponno RB,Mbaveng AT,
Tapondjou AL,Meyer JJM, Barboni L,
et al. Antibacterial activities of the
extracts, fractions and compounds from
Dioscorea bulbifera. BMCComplementary
and AlternativeMedicine. 2012;12:228.
DOI: 10.1186/1472-6882-12-228
[38] FouotsaH,MbavengAT,MbazoaCD,
Nkengfack AE, Farzana S, Iqbal C, et al.
Antibacterial constituents of three
Cameroonianmedicinal plants:Garcinia
nobilis,Oricia suaveolens and Balsamocitrus
camerunensis. BMCComplementary and
AlternativeMedicine. 2013;13:81. DOI:
10.1186/1472-6882-13-81
[39]Mbaveng AT, Kuete V, Ngameni B,
Beng VP, Ngadjui BT, Meyer JJM, et al.
Antimicrobial activities of the methanol
extract and compounds from the twigs
of Dorstenia mannii (Moraceae). BMC
Complementary and Alternative
Medicine. 2012;12:83. DOI: 10.1186/
1472-6882-12-83
[40]Dongfack MDJ, Lallemand M-C,
Kuete V, Mbazoa CD, Wansi JD,
Dufat H, et al. A new Sphingolipid and
Furocoumarins with antimicrobial
activity from Ficus exasperate. Chemical
& Pharmaceutical Bulletin. 2012;60:
1072-1075. DOI: 10.1248/cpb.c12-00279
[41] Ango YP, Kapche DWFG, Kuete V,
Ngadjui BT, Bezabih M, Abegaz BM.
Chemical constituents of Trilepisium
madagascariense (Moraceae) and their
antimicrobial activity. Phytochemistry
Letters. 2012;5:524-528. DOI: 10.1016/j.
phytol.2012.05.006
[42] Tankeo SB, Damen F,
Awoufack MD, Mpetga J, Tane P,
Eloff JN, et al. Antibacterial activities of
the methanol extracts, fractions and
compounds from Fagara tessmanii.
Journal of Ethnopharmacology. 2015;169:
275-279. DOI: 10.1016/j.jep.2015.04.041
[43] Tankeo SB, Damen F, Sandjo LP,
Tane P, Kuete V. Antibacterial activities
of the methanol extracts, fractions and
compounds from Harungana
madagascariensis. Journal of
Ethnopharmacology. 2016;190:100-105.
DOI: 10.1016/j.jep.2016.06.005
[44]Djeussi DE, Sandjo LP,
Noumedem JAK, Omosa LK,
Ngadjui BT, Kuete V. Antibacterial
21
Plant-Derived Compounds against Microbial Infections and Cancers
DOI: http://dx.doi.org/10.5772/intechopen.92596
activities of the methanol extracts and
compounds from Erythrina sigmoidea
against Gram-negative multi-drug
resistant phenotypes. BMC
Complementary and Alternative
Medicine. 2015;15:453. DOI: 10.1186/
s12906-015-0978-8
[45]Mbaveng AT, Sandjo LP, Tankeo SB,
Ndifor AR, Pantaleon AA, Nagdjui BT,
et al. Antibacterial activity of nineteen
selected natural products against multi-
drug resistant Gram-negative
phenotypes. Springerplus. 2015;4:823.
DOI: 10.1186/s40064-015-1645-8
[46]Ouete JLN, Sandjo LP,
Kapche DDW, Yeboah SO, Mapitse P,
Abegaz BM, et al. Excelsoside: A new
benzylic diglycoside from the leaves of
Milicia excelsa. Zeitschrift für
Naturforschung. 2014;69:271-275. DOI:
10.5560/ZNC.2014-0087
[47]Ouete JLN, Sandjo LP,
Kapche DDW, Liermann JC, Opatz T,
Simo IK, et al. A new flavone from the
roots ofMilicia excelsa (Moraceae).
Zeitschrift für Naturforschung.
Section C. 2013;68:259-263. DOI:
10.5560/ZNC.2013.68c0259
[48]Nganou BK, Konga IS, Fankam AG,
Bitchagno GTM, Sonfack G, Nayim P,
et al. Guttiferone BL with antibacterial
activity from the fruits of Allanblackia
gabonensis. Natural Product Research.
2018;33:2638-2646. DOI: 10.1080/
14786419.2018.1465424
[49]Dzotam JK, Simo IS, BitchagnoGTM,
Celik I, Sandjo LP, Tane P, et al. In vitro
antibacterial and antibiotic modifying
activity of crude extract, fractions and
30,40,7-trihydroxyflavone fromMyristica
fragransHoutt againstMDRGram-
negative enteric bacteria. BMC
Complementary and Alternative
Medicine. 2018;18:15. DOI: 10.1186/
s12906-018-2084-1
[50]Damen F, Demgne OMF,
Bitchagno GTM, Celik I, Mpetga JDS,
Tankeo SB, et al. A new polyketide from
the bark of Hypericum roeperianum
Schimp. (Hypericaceae). Natural
Product Research. 2019. DOI: 10.1080/
14786419.2019.1677655
[51]Mambou CS, Nono RN, Chouna JR,
Tamokou JDD, Nkeng-Efouet-Alango P,
Sewald N. Antibacterial secotirucallane
triterpenes from the stem bark of
Pseudocedrela kotschyi. Zeitschrift für
Naturforschung. 2018;73:241-246. DOI:
10.1515/znc-2017-0207
[52] Chouna JR, Tamokou JDD, Nkeng-
Efouet-Alango P, Lenta BN, Sewald N.
Antimicrobial triterpenes from the stem
bark of Crossopteryx febrifuga.
Zeitschrift für Naturforschung. 2015;70:
169-173. DOI: 10.1515/znc-2014-4168
[53]Devkota KP, Lenta BN, Wansi JD,
Sewald N. Antibacterial constituents
from Leucosceptrum canum.
Phytochemistry Letters. 2009;3:24-28.
DOI: 10.1016/j.phytol.2009.10.007
[54]Hussein IA, Srivedavyasasri R, El-
Hela AA, Mohammad AI, Ross SA.
Antimicrobial secondary metabolites
from Silene rubella growing in Egypt.
Journal of Biomedical and
Pharmaceutical Research. 2019;8. DOI:
10.32553/jbpr.v8i6.694
[55]Dzoyem JP, Melong R, Tsamo AT,
Tchinda AT, Kapche DGWF,
Ngadjui BT, et al. Cytotoxicity,
antimicrobial and antioxidant activity of
eight compounds isolated from Entada
abyssinica (Fabaceae). BMC Research
Notes. 2017;10:118. DOI: 10.1186/
s13104-017-2441-z
[56] Ali B, Al-Wabel NA, Shams S,
Ahamad A, Khan SA, Anwar F. Essential
oils used in aromatherapy: A systemic
review. Asian Pacific Journal of Tropical
Biomedicine. 2015;5:601-611. DOI:
10.1016/j.apjtb.2015.05.007
[57] Alali F, El-elimat T, Albataineh H,
Al-balas Q, Al-gharaibeh M,
22
Bioactive Compounds
Falkinham JO, et al. Cytotoxic
Homoisoflavones from the bulbs of
Bellevalia eigii. Journal of Natural
Products. 2015;78:1708-1715. DOI:
10.1021/acs.jnatprod.5b00357
[58] El-elimat T, Rivera-chávez J,
Burdette JE, Czarnecki A,
Alhawarri MB, Al-gharaibeh M, et al.
Cytotoxic homoisoflavonoids from the
bulbs of Bellevalia flexuosa. Fitoterapia.
2018;127:201-206. DOI: 10.1016/j.
fitote.2018.02.022
[59]Dai Y, Harinantenaina L, Brodie PJ,
Goetz M, Shen Y, Tendyke K, et al.
Antiproliferative Homoisoflavonoids
and Bufatrienolides from Urginea
depressa. Journal of Natural Products.
2013;76:865-872. DOI: 10.1021/
np300900a
[60]Dang NH, Chung ND, Tuan HM,
Hiep NT, Dat NT. Cytotoxic
Homoisoflavonoids from Ophiopogon
japonicus tubers. Biological &
Pharmaceutical Bulletin. 2016;65:
204-207. DOI: 10.1248/cpb.c16-00743
[61] Zhou C, Zou L, Mo J, Wang X,
Yang B, He Q. Homoisoflavonoids from
Ophiopogon japonicus. Helvetica Chimica
Acta. 2013;96:1397-1405. DOI: 10.1002/
hlca.201200493
[62]Ghoran SH, Saeidnia S, Babaei E,
Kiuchi F, Hussain H, Plants M, et al.
Scillapersicene: A new
homoisoflavonoid with cytotoxic
activity from the bulbs of Scilla persica.
Natural Product Research. 2015;30:
1309-1314. DOI: 10.1080/
14786419.2015.1054286
[63]Mbaveng AT, Bitchagno GTM,
Kuete V, Tane P, Thomas E.
Phytomedicine cytotoxicity of
ungeremine towards multi-factorial
drug resistant cancer cells and induction
of apoptosis , ferroptosis, necroptosis
and autophagy. Phytomedicine. 2019;
60:152832. DOI: 10.1016/j.phymed.
2019.152832
[64]Doan H, Mai T, Toan TP, Huu GT,
Le TN, Thi V, et al. New flavonoid and
stilbene derivatives from the fruits of
Macaranga balansae. Natural Product
Research. 2019. DOI: 10.1080/
14786419.2019.1587425
[65] Zakaria I, Ahmat N, Jaafar FM,
Widyawaruyanti A. Flavonoidswith
antiplasmodial and cytotoxic activities of
Macaranga triloba. Fitoterapia. 2012;83:
968-972. DOI: 10.1016/j.
fitote.2012.04.020
[66]Mai T, Doan H, Nguyen TL,
Van TT, Vu VN, Phi TD, et al. Cytotoxic
phenolic compounds from fruit
glandular trichomes ofMacaranga
tanarius. Journal of Analytical Methods
in Chemistry. 2019;2019:2917032. DOI:
10.1155/2019/2917032
[67]Wei H, Zhang X,WuG, Yang X,
Pan S,WangY, et al. Chalcone derivatives
from the fernCyclosorus parasiticus and
their anti-proliferative activity. Food and
Chemical Toxicology. 2013;60:147-152.
DOI: 10.1016/j.fct.2013.07.045
[68]Hashim NM, Rahmani M, Cheng G,
Ee L, Sukari MA, Yahayu M, et al.
Antiproliferative activity of xanthones
isolated from Artocarpus obtusus.
BioMed Research International. 2012;
2012:130627. DOI: 10.1155/2012/130627
[69]Mah SH, Cheng G, Ee L, Teh SS,
Sukari MA. Antiproliferative xanthone
derivatives from Calophyllum
inophyllum and Calophyllum soulattri.
Pakistan Journal of Pharmaceutical
Sciences. 2012;28:425-429
[70] Ji F, Li Z, Liu G, Niu S, Zhao N,
Liu X, et al. Xanthones with
Antiproliferative effects on prostate
cancer cells from the stem bark of
Garcinia xanthochymus. Natural Product
Communications. 2012;7:53-56. DOI:
10.1177/1934578X1200700119
[71]Deng A-J, Qin H-L. Cytotoxic
dihydrobenzophenanthridine alkaloids
23
Plant-Derived Compounds against Microbial Infections and Cancers
DOI: http://dx.doi.org/10.5772/intechopen.92596
from the roots ofMacleaya microcarpa.
Phytochemistry. 2010;71:816-822. DOI:
10.1016/j.phytochem.2010.02.007
[72] Luo Z, Wang F, Zhang J, Li X,
Zhang M, Hao X. Cytotoxic alkaloids
from the whole plants of Zephyranthes
candida. Journal of Natural Products.
2012;75:2113-2120. DOI: 10.1021/
np3005425
[73] Bosio C, Tomasoni G, Martínez R,
Olea AF, Villena J. Cytotoxic and
apoptotic effects of leptocarpin, a plant-
derived sesquiterpene lactone, on
human cancer cell lines. Chemico-
Biological Interactions. 2015;242:
415-421. DOI: 10.1016/j.cbi.2015.11.006
[74] Ford CD, Ulloa JL, Catalán CAN,
Grau A, Martino VS, Muschietti LV,
et al. The sesquiterpene lactone
polymatin B from Smallanthus
sonchifolius induces different cell death
mechanisms in three cancer cell lines.
Phytochemistry. 2015;117:332-339. DOI:
10.1016/j.phytochem.2015.06.020
[75] Jimenez-usuga S, Malafronte N,
Cotugno R, Leo MD, Osorio E,
Tommasi ND. New sesquiterpene
lactones from Ambrosia cumanensis
Kunth. Fitoterapia. 2016;113:170-174.
DOI: 10.1016/j.fitote.2016.07.019
[76] Shulha O, Çiçek SS, Piccolella S,
Rárová L, Strnad M, Sönnichsen F, et al.
Sesquiterpene lactones from Sonchus
palustris L. (Asteraceae, Cichorieae).
Phytochemistry. 2020;170:112196. DOI:
10.1016/j.phytochem.2019.112196
[77] Carpesium L, Wang L, Qin W,
Tian L, Zhang X, Lin F, et al.
Caroguaianolide A-E, five new cytotoxic
sesquiterpene lactones from Carpesium
abrotanoides L. Fitoterapia. 2016;127:
349-355. DOI: 10.1016/j.fitote.2018.
03.015
[78] Xu X-K, Ye J, Chen L, Zhang W,
Yang Y, Li H. Four new isomeric
sesquiterpene lactone dimers from
Carpesium faberi. Tetrahedron Letters.
2015;56:6381-6384. DOI: 10.1016/j.
tetlet.2015.09.127
[79] Xu X-Y, Sun P, Guo D, Liu X, Liu J,
Hu L. Cytotoxic sesquiterpene lactone
dimers isolated from Inula japonica.
Fitoterapia. 2015;101:218-223. DOI:
10.1016/j.fitote.2015.01.011
[80] Shim JS, Kim JH, Lee JY, Kim SN,
Kwon HJ. Anti-angiogenic activity of a
homoisoflavanone from Cremastra
appendiculata. Planta Medica. 2004;70:
171-173. DOI: 10.1055/s-2004-815496
[81]Han N, Yang Z, Liu Z, Liu H, Yin J.
Research progress on natural
Benzophenanthridine alkaloids and
their pharmacological functions: A
review. Natural Product
Communications. 2016;11:1181-1188.
DOI: 10.1177/1934578X1601100838
[82]Garcia-Pineres AJ, Castro V,
Mora G, Schmidt TJ, Strunck E,
Pahl HL, et al. Cysteine 38 in p65/NF-
kappaB plays a crucial role in DNA
binding inhibition by sesquiterpene
lactones. The Journal of Biological
Chemistry. 2001;276:39713. DOI:
10.1074/jbc.M101985200
[83] Ghantous A, Gali-Muhtasib H,
Vuorela H, Saliba NA, Darwiche N.
What made sesquiterpene lactones
reach cancer clinical trials? Drug
Discovery Today. 2010;15:668-678. DOI:
10.1016/j.drudis.2010.06.002
[84] Kwok BH, Koh B, Ndubuisi MI,
Elofsson M, Crews CM. The anti-
inflammatory natural product
parthenolide from the medicinal herb
feverfew directly binds to and inhibits
IkappaB kinase. Chemistry & Biology.
2001;8:759. DOI: 10.1016/s1074-5521
(01)00049-7
[85] Zunino SJ, Ducore JM, Storms DH.
Parthenolide induces significant
apoptosis and production of reactive
oxygen species in high-risk pre-B
24
Bioactive Compounds
leukemia cells. Cancer Letters. 2007;
254:119-127. DOI: 10.1016/j.
canlet.2007.03.002
[86]Hung W-L, Suh JH, Wang Y.
Chemistry and health effects of
furanocoumarins in grapefruit. Journal
of Food and Drug Analysis. 2017;25:
71-83. DOI: 10.1016/j.jfda.2016.11.008
[87] Kashman Y, Gustafson KR,
Fuller RW, Cardellin JH, McMahon JB,
Currens MJ, et al. The calanolides, a
novel HIV inhibitory class of coumarin
derivatives from the tropical rainforest
tree, Calophyllum lanigerum. Journal of
Medicinal Chemistry. 1992;35:
2735-2743. DOI: 10.1021/jm00093a004
[88] Lee YJ, Lee YJ, Im JH, Won SY,
Kim YB, Cho MK, et al. Synergistic anti-
cancer effects of resveratrol and
chemotherapeutic agent clofarabine
against human malignant mesothelioma
MSTO-211H cells. Food and Chemical
Toxicology. 2012;52:61-68. DOI:
10.1016/j.fct.2012.10.06
25
Plant-Derived Compounds against Microbial Infections and Cancers
DOI: http://dx.doi.org/10.5772/intechopen.92596
